Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sapphire Biotech
San Diego, California, United Statessapphirebiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sapphire Biotech was a California-based oncology biotech that developed preclinical small molecule inhibitors of QSOX1 for cancer therapy and rapid QSOX1-L biomarker diagnostic tests. Their anti-metastatic compounds included SPX-1009, which demonstrated higher potency than SBI-183. The company was acquired by AXIM Biotechnologies in January 2020.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Mayo ClinicArizona State UniversitySkysong Innovations (licensing partner)
Beyond the preview
Go deeper on Sapphire Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sapphire Biotech.